ADC Therapeutics Director Azelby Sells Shares Amid Price Target Cut
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
- Latest
- Trending
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
"Riot Platforms expands stock pool, updates severance terms for execs, and doubles authorized shares to 680M for future growth in ...
"Learn how to build a dream finance team amid AI automation, high CFO turnover, and changing market conditions. Insights from ...
Rollblock's revenue share model attracts Solana and Dogecoin investors amid market shifts, promising higher returns and significant growth potential.
Explore the cutting-edge hardware demands for artificial consciousness, delving into compute capacity and advanced infrastructure in Part I of this ...
Crypto analyst Vapor predicts meme coins like Dogecoin and Shiba Inu will lead the altcoin season, offering high potential gains ...
Zuora acquires AI-driven Sub(x) to enhance subscriber insights and adaptive paywall solutions, promising quicker revenue growth and better consumer engagement.
Discover if the iShares Select Dividend ETF is the right Large Cap Value addition to your portfolio. Analyzing performance, costs, ...
Meta faces lawsuit by billionaire Andrew Forrest over fake crypto ads using his likeness, U.S. judge allows negligence and misappropriation ...
"Bitcoin NFTs soar with $148M in sales, surpassing Ronin amid an altcoin slump; Shiba Inu and Avalanche lead declines, market ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.